Seite auswählen

The British private equity firm Cinven has announced the acquisition of Amdipharm, an international speciality pharmaceutical company, for £367 million.

Amdipharm will initially operate as an independent company, and then over time merge with the pharmaceutical company pharmaceuticals Mercury, which took over Cinven in September 2012.

The London-based private equity firm pushes ahead with this transaction, as part of the implementation of its consolidation strategy within the speciality pharmaceutical industry, making ​​this the fourth investment from the Investment Fund V and the fifth investment in 2012 in total.

Amdipharm pharmaceutical products‘ home market is in the UK, but are available in over 80 countries globally.

[ilink url=““] Link zur Quelle (Ärzte Zeitung)[/ilink]